Johnson & Johnson suspends clinical study of EPI-7386 due to difficulty in patient recruitment
ADC评论
November 1, 2022
On October 31, ESSA Pharma announced that Johnson & Johnson/Janssen Pharmaceuticals will discontinue a Phase I combination therapy clinical study of its lead candidate, EPI-7386,
